HER2-specific affibody-conjugated thermosensitive liposomes (affisomes) for improved delivery of anticancer agents

Journal of Liposome Research

Volumn 18, Issue 4, 2008, Pages 293-307

  Puri, Anu ^a   Kramer Marek, Gabriela ^b   Campbell Massa, Ryan ^a   Yavlovich, Amichai ^a   Tele, Shrikant C ^a   Lee, Sang Bong ^b   Clogston, Jeffrey D ^c   Patri, Anil K ^c   Blumenthal, Robert ^a   Capala, Jacek ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Affibody; Affisomes; Breast tumor targeting; Drug delivery; Thermosensitive liposomes; Triggered release

Indexed keywords

ANTINEOPLASTIC AGENT; ARGON; CALCEIN; CYSTEINE; DIPALMITOYLPHOSPHATIDYLCHOLINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUORESCENT DYE; LIPOSOME; PHOSPHATE BUFFERED SALINE; PHOSPHATIDYLCHOLINE; TRIBUTYLPHOSPHINE;

ARTICLE; ATMOSPHERE; CARBOXY TERMINAL SEQUENCE; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG TARGETING; FETAL CALF SERUM; HEAT SENSITIVITY; INCUBATION TIME; PRIORITY JOURNAL; ROOM TEMPERATURE; TEMPERATURE; ULTRASOUND;

ANIMALS; ANTINEOPLASTIC AGENTS; CATTLE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; LIPOSOMES; MOLECULAR STRUCTURE; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TEMPERATURE;

EID: 56749152175     PISSN: 08982104     EISSN: 15322394     Source Type: Journal    
DOI: 10.1080/08982100802457377     Document Type: Article

References (21)

1. Allen, T. M. (1994) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol Sci 15:215-220.
2. Allen, T. M. (1997) Liposomes. Opportunities in drug delivery. Drugs 54 Suppl 4, 8-14.
3. Cattel, L., Ceruti, M., and Dosio, F. (2003) From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 89:237-249.
4. Gabizon, A. and Martin, F. (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 Suppl 4, 15-21.
5. Gupta, C. M., Bali, A. (1981). Biochim Biophys Acta 663:506-515.
6. Hussein, M. (2003). Pegylated liposomal doxorubicin, vincristine, and reduced-dose dexamethasone as first-line therapy for multiple myeloma. Clin Lymphoma 4 Suppl 1, S18-S22.
7. Needham, D., Anyarambhatla, G., Kong, G., and Dewhirst, M. W. (2000) A new temperature-sensitive liposome for use with mild hyperthermia: characterization and testing in a human tumor xenograft model. Cancer Res 60:1197-1201.
8. Needham, D. and Dewhirst, M. W. (2001) The development and testing of a new temperature-sensitive drug delivery system for the treatment of solid tumors. Adv Drug Deliv Rev 53:285-305.
9. Nellis, D. F., Ekstrom, D. L., Kirpotin, D. B., Zhu, J., Andersson, R., Broadt, T. L., Ouellette, T. F., Perkins, S. C., Roach, J. M., Drummond, D. C., Hong, K., Marks, J. D., Park, J. W., and Giardina, S. L. (2005) Preclinical manufacture of an anti-HER2 scFv-PEG-DSPE, liposome-inserting conjugate. 1. Gram-scale production and purification. Biotechnol Prog 21:205-220.
10. Nellis, D. F., Giardina, S. L., Janini, G. M., Shenoy, S. R., Marks, J. D., Tsai, R., Drummond, D. C., Hong, K., Park, J. W., Ouellette, T. F., Perkins, S. C., and Kirpotin, D. B. (2005) Preclinical manufacture of anti-HER2 liposome-inserting, scFv-PEG-lipid conjugate. 2. Conjugate micelle identity, purity, stability, and potency analysis. Biotechnol Prog 21:221-232.
11. Noble, C. O., Kirpotin, D. B., Hayes, M. E., Mamot, C., Hong, K., Park, J. W., Benz, C. C., Marks, J. D., and Drummond, D. C. (2004) Development of ligand-targeted liposomes for cancer therapy. Expert Opin Ther Targets 8:335-353.
12. Orlova, A., Tolmachev, V., Pehrson, R., Lindborg, M., Tran, T., Sandstrom, M., Nilsson, F. Y., Wennborg, A., Abrahmsen, L., and Feldwisch, J. (2007) Synthetic affibody molecules: a novel class of affinity ligands for molecular imaging of HER2-expressing malignant tumors. Cancer Res 67:2178-2186.
13. Park, J. W. (2002) Liposome-based drug delivery in breast cancer treatment. Breast Cancer Res 4:95-99.
14. Park, J. W., Benz, C. C., and Martin, F. J. (2004) Future directions of liposome- and immunoliposome-based cancer therapeutics. Semin Oncol 31:196-205.
15. Park, J. W., Hong, K., Kirpotin, D. B., Colbern, G., Shalaby, R., Baselga, J., Shao, Y., Nielsen, U. B., Marks, J. D., Moore, D., Papahadjopoulos, D., and Benz, C. C. (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8:1172-1181.
16. Ponce, A. M., Vujaskovic, Z., Yuan, F., Needham, D., and Dewhirst, M. W. (2006) Hyperthermia mediated liposomal drug delivery. Int J Hyperthermia 22:205-213.
17. Sapra, P., Tyagi, P., and Allen, T. M. (2005) Ligand-targeted liposomes for cancer treatment. Curr Drug Deliv 2:369-381.
18. Torchilin, V. P. (1985) Liposomes as targetable drug carriers. Crit Rev Ther Drug Carrier Syst 2:65-115.
19. Torchilin, V. P. (2005) Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 4:145-160.
20. Weinstein, J. N., Magin, R. L., Zaharko, D. S., Yatvin, M. B., and Blumenthal, R. (1979) Use of Hyperthermia for Selective Localization of Liposomal Methotrexate in Tumors. Biophysical Journal 25:A291.
21. Yatvin, M. B., Weinstein, J. N., Dennis, W. H., and Blumenthal, R. (1978) Design of liposomes for enhanced local release of drugs by hyperthermia. Science 202:1290-1293.